Maridebart cafraglutide
Also known as: AMG 133, AMG-133, MariTide
Classification
Peptide
Regulatory Status
n/a
Sources
3
Review
n/a
Overview
Maridebart cafraglutide combines GLP-1 receptor agonism with glucose-dependent insulinotropic polypeptide (GIP) receptor antagonism in an antibody-peptide conjugate format (per Phase 2 trial BACKGROUND).
Evidence and limitations
Human/preclinical evidence breakdown is not available in this record.
Pathways
Interactions & cautions
Drug interactions
other GLP-1 or dual-incretin agonists — Class overlap with incretin therapies (GI effects, delayed gastric emptying context) is expected; no approved interaction table exists yet. (review)
These are observational flags for review, not individualized instructions.
Sources
Educational reference only — not medical advice.
What people report (anecdote)
CLINICAL DATA (from trials)
Adverse events:
None recorded in our sources.
Effects measured:
Human trials: none found.
ANECDOTE
What people report: anecdote, not evidence
Loading…
Submit a claim you saw